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Abstract
Cancers originating from epithelial cells are the most
common malignancies. No common expression profile
of solid tumors compared to normal tissues has been
described so far. Therefore we were interested if genes
differentially expressed in the majority of carcinomas
could be identified using bioinformatic methods.
Complete data sets were downloaded for carcinomas
of the prostate, breast, lung, ovary, colon, pancreas,
stomach, bladder, liver, and kidney, and were sub-
jected to an expression analysis using SAM. In each
experiment, a gene was scored as differentially ex-
pressed if the q value was below 25%. Probe identifiers
were unified by comparing the respective probe
sequences to the Unigene build 155 using BlastN. To
obtain differentially expressed genes within the set of
analyzed carcinomas, the number of experiments in
which differential expression was observed was
counted. Differential expression was assigned to
genes if they were differentially expressed in at least
eight experiments of tumors from different origin. The
identified candidate genes ADRM1, EBNA1BP2, FDPS,
FOXM1, H2AFX, HDAC3, IRAK1, and YY1 were sub-
jected to further validation. Using this comparative
approach, 100 genes were identified as upregulated
and 21 genes as downregulated in the carcinomas.
Neoplasia (2004) 6, 744–750
Keywords: Cancer, tumor, microarray, comparative analysis, FOXM1.
Introduction
Solid tumors are the second most common cause of death
in the western world. Besides very few successes in rare
solid tumors such as testicular cancer, the survival rate of
most of these tumors is still low. However, many of these
tumors are characterized by inactivating mutations of com-
mon tumor-suppressor genes, such as p53, p16, or Rb, and
activation of oncogenes such as Her2/neu [1,2]. Therefore
one might guess that not only these genes are differentially
expressed within a broad range of tumors, but that there are
also other undescribed genes that are differentially
expressed in the majority of tumors.
Large-scale gene expression analysis by means of
microarrays has yielded large sets of class 2 cancer genes
[3]. This enables us to compare the expression profiles of
various tumors and to generate sets of common differentially
expressed genes. These genes would then represent a pool of
interesting candidates used to give new insights into tumor
development, and are candidates for new targets for therapy
and diagnostics in a variety of cancers. Attempts have been
made to compare the gene expression profiles of tumors of
a single entity and to assign differentially expressed genes
[4–9]. In addition, gene expression differences of tumors
from diverse organs have been analyzed with various
approaches [10–20].
Gene expression profiles are obtained by different techni-
ques such as DDRT-PCR, SAGE, expressed sequence tag
(EST) sequencing, or microarrays [21,22]. Moreover, within the
field of microarrays, there are at least three different rival
technologies. The most often used techniques, Affymetrix
GeneChips and cDNA on glass microarrays, generate different
data types and are accompanied by their own challenges within
data preprocessing, leading to sets of gene expression data
that are not easy to compare [23].
To identify common differentially expressed genes in solid
tumors and to overcome these limitations, we have analyzed
the differential expression of genes within each experiment by
a single method with defined thresholds for 11 different carci-
nomas. We identified a set of 121 differentially expressed
genes and validated eight of these using dot blots containing
the transcriptome of different solid cancers.
Materials and Methods
Data Sets
Only data sets containing values for tumors and normal
tissues were selected. Data sets for gene expression profiles
were obtained by downloading the expression values in
tabular form from the Stanford microarray database (http://
genome-www5.stanford.edu//), GEO (http://www.ncbi.nlm.
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nih.gov/geo/), and the supplementary information of pub-
lished manuscripts (Table 1). All data sets were used as
provided and were normalized if needed by median center-
ing. To unify the used gene identifiers, all probe sequences
were compared against the Unigene database version 155
using the BlastN program [24]. Sequences were assigned to
a Unigene cluster if their homology was below an e value
of e100, or if their score was higher than 1.5 per base
analyzed. Data from the following tumors have been ac-
quired: prostate, breast, lung, ovary, colon, pancreas, stom-
ach, bladder, liver, and kidney.
Identification of Differentially Expressed Genes
All experiments were analyzed using the SAM package
(http://www-stat.stanford.edu/ftibs/SAM/index.html) with a
cutoff of 25% as q value. To the probes identified by this
approach, we assigned the value of 1 if they were overex-
pressed in the tumor, or1 if they were underexpressed. If a
probe was not differentially expressed, we assigned 0; if it
was not analyzed in a given experiment, we assigned a blank
field. For all probes, we counted the number of differential
expression. To identify genes differentially expressed in the
majority of carcinomas, we called only those genes as
differentially expressed, which displayed a differential ex-
pression within eight of the analyzed 11 cancer entities
(73%). For the cancer entities of the kidney, lung, and
prostate, we obtained more than one data set. For these,
differentially expressed genes were identified by each ex-
periment as mentioned above. Subsequently, within a type of
cancer (e.g., prostate cancer), the differentially expressed
genes were compared and scored as differential only if they
were identified within at least 50% of the experiments. Thus,
for prostate cancer, genes were counted as differentially
expressed if they had been identified within at least two
experiments—for kidney and lung cancer, if they had been
identified within at least one experiment. Such genes were
then counted only once for the comparison between the
different cancer entities.
Validation of Differential Expression
CDNA clones for ADRM1 (accession no. BM913272),
EBNA1BP2 (BU541488), FDPS (BQ877587), FOXM1
(BQ691509), H2AFX (BG757479), HDAC3 (BM468317),
IRAK1 (BE250451), and YY1 (BE746736) were obtained
from the RZPD (www.rzpd.de) and prepared using the
GFX Micro Plasmid Prep kit according to the manufacturer’s
recommendation (Amersham Pharmacia Biotech, Freiburg,
Germany). The identity of the inserts of the obtained clones
was confirmed by sequencing of the clones with an ABI 3700
sequencer and BigDye terminators (Applied Biosystems,
Weiterstadt, Germany). For the derived sequences, we
analyzed their identity against the clones using the program
BlastN and the Unigene database. The inserts of the clones
were prepared by digesting the DNA with the appropriate
restriction enzymes and purification from agarose gels. The
fragments were labelled with a-32P-dCTP (f6.000 Ci/mmol)
using the Rediprime II kit (Amersham Pharmacia Biotech)
and hybridized to a cancer profiling array II (CPA II) using
the ExpressHyb hybridization solution according to the
manufacturer’s recommendations (Clontech, Heidelberg,
Germany).
Autoradiographs were obtained by using a BAS-II scan-
ner (Raytest, Eggenfelden, Germany). For further analysis,
intensities were normalized to b-actin and divided by the
normalized intensities of the corresponding normal tissues.
These data were subjected to visualization using Treeview
(http://rana.lbl.gov/EisenSoftware.htm).
Table 1. Used Gene Expression Profiling Data Sets.
Reference Tissue Type of tumor Type of
microarray
Number of tumor Number of
normal
Number of
probes/probesets
Source of
data
Dyrskjot et al. [30] Bladder Carcinoma Affymetrix 10 4 8,793 GEO
Sorlie et al. [19] Breast Carcinoma cDNA 68 4 8,102 SMD
Notterman et al. [18] Colon Adenocarcinoma Affymetrix 18 18 7,129 Supplement
Boer et al. [11] Kidney Renal cell carcinoma cDNA 32 32 31,500 GEO
Higgins et al. [15] Kidney Renal cell carcinoma cDNA 24 3 22,648 SMD
Chen et al. [12] Liver Hepatocellular
carcinoma
cDNA 82 75 23,075 SMD
Garber et al. [14] Lung Adenocarcinoma
and squamous cell
carcinoma
cDNA 36 (A) and
13 (S)
5 8,102 SMD
Bhattacharjee et al. [10] Lung Adenocarcinoma
and squamous cell
carcinoma
Affymetrix 127 (A) and
21 (S)
17 12,625 Supplement
Welsh et al. [20] Ovary Adenocarcinoma Affymetrix 27 5 8,793 Supplement
Iacobuzio-Donahue et al. [16] Pancreas Adenocarcinoma cDNA 11 5 44,500 SMD
Dhanasekaran et al. [13] Prostate Adenocarcinoma cDNA 10 9 9,948 Supplement
Luo et al. [31] Prostate Adenocarcinoma cDNA 16 9 6,500 Supplement
Singh et al. [32] Prostate Adenocarcinoma Affymetrix 52 50 12,625 Supplement
Welsh et al. [33] Prostate Adenocarcinoma Affymetrix 25 9 8,793 Supplement
Leung et al. [17] Stomach Adenocarcinoma cDNA 89 23 44,500 SMD
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Results
Overlap of Data Sets
A prerequisite for a comparative analysis of gene expres-
sion differences is that a high number of genes are analyzed
in more than one experiment. This is especially true for
comparisons using microarray data sets with incomplete
genome representation. However, within the data sets used,
the majority of genes is analyzed by at least six experiments,
and more than 4000 genes are interrogated by at least eight
experiments (Figure 1A).
Identification of Differential Expression
Assignment of significance values is a common proce-
dure in the analysis of gene expression. There are several
algorithms known, but the obtained values are rarely cor-
rected for multiple testing. To control the error associated
with multiple testing, we used the software SAM (http://www-
stat.stanford.edu/ftibs/SAM/index.html). We tested several
cutoffs for the q value generated by SAM in a comparison of
four different prostate experiments. From these results, we
concluded that a cutoff of 25% would be sensitive enough to
generate a list of common differentially expressed genes
because we found an overlap of 50% with the data set
generated by Rhodes et al. [25] (data not shown). We also
tried to use only those genes with a cutoff below 5%, but
failed to identify differentially expressed genes in several
studies, probably due to a high data variance, which could in
part be attributed to a low sample number of normal tissues
in different studies (data not shown). When we analyzed the
frequency of classification of a gene as differentially
expressed, we observed that most of the genes were never
classified as differentially expressed and only a minor num-
ber were classified more than five times (Figure 1, B and C).
Because we were interested to further analyze genes differ-
entially expressed in the majority of investigated tumors, we
chose to examine genes differentially expressed in at least
eight tumors. Using this threshold, we identified 100 genes
as commonly upregulated and 21 as commonly downregu-
lated in 11 different cancer types from 10 different tissues, as
listed in Figure 2A. Within this set, we identified genes such
as PCNA and OSF-2, which are well known to be overex-
pressed within human carcinomas. We then classified the
differentially expressed genes according to their purposed
function (www.geneontology.org; Figure 3). However, for
most of the identified genes, a function has not assigned
yet. Of these genes that were characterized by a category,
most of them were grouped into the category of metabo-
lism and cell growth/maintenance. Differences in the distri-
bution of the assigned categories between normal and
tumor genes could not be observed. Annotation of the
genes revealed that many of the genes are either transcrip-
tional regulators, or take part in the degradation of proteins
(Figure 2A).
Validation of Differential Expression
We selected eight upregulated genes based on their
degree of differential expression and proposed function
(ADRM1, EBNA1BP2, FDPS, FOXM1, H2AFX, HDAC3,
IRAK1, and YY1) and investigated their differential expres-
sion by hybridization of a gene-specific probe to a CPA II.
The CPA II filter contains the transcriptome from 19 different
tumor entities. Each tumor is represented by more than one
sample, and a corresponding sample of normal tissue from
the same donor is provided. For each of the spots on the
array, we also obtained the expression values for b-actin as a
‘‘housekeeping’’ control. To evaluate the differential expres-
sion of the genes, we divided each value by the corres-
ponding spot value of b-actin. Furthermore, we divided the
normalized values of the tumor by the corresponding normal
values (Figure 2B). As expected, most of these genes were
overexpressed in a number of samples of different tumor
entities displaying the validity of our approach, though we
could not observe any upregulation of the genes within the
kidney tissues analyzed. Also, only sporadic upregulation
was seen in the mammary tumor samples. This might argue
against our approach although, except for FOXM1, none of
the genes was identified as overexpressed in kidney cancer
by our comparative analysis and only five (ADRM1,
EBNA1BP2, FDPS, FOXM1, and H2AFX) were identified in
Figure 1. (A) Histogram of the number of genes analyzed by the different experiments. (B and C) Histogram of the number of genes found to be differentially
expressed in the different experiments: (B) overexpressed; (C) underexpressed. Interestingly, we did not find a gene that is underexpressed in more than nine
experiments, indicating a more heterogeneous gene expression in normal tissues of different origins. X-axis: number of experiments; Y-axis: number of genes.
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Figure 2. (A) A total of 121 common differentially expressed genes. Red: Overexpressed in tumors; green: underexpressed in tumors; black: not differentially
expressed; grey: not investigated in the original study. Within our comparison, values of +1 for overexpression and 1 for underexpression are assigned.
Therefore, no graduations of differential expression are shown. (B) Heatmap of expression of the selected genes on the CPA II. Intensity values for the gene of
interest were normalized by the value of -actin of the respective probe and then divided by the normalized value of the corresponding normal tissue.
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breast cancer. Also, we were not able to analyze the quality
of the samples in detail. We observed also the heterogeneity
of gene expression in the different tumor entities. In our
comparative analysis, FOXM1 was overexpressed in 10 of
11 different tumors. This is reflected by the high overexpres-
sion of FOXM1 in nearly every tumor analyzed. However,
overexpression of FOXM1 could not be observed for some
samples of different origins.
Discussion
In an attempt to identify genes commonly overexpressed
within solid tumors, we have compared gene expression
profiling experiments of 11 different tumors from 10 different
organs. We identified the differentially expressed genes
using a comparative analysis. The major challenge herein
was to unify the different identifiers of the experiments. The
data sets used were derived from different microarrays plat-
forms with different structures of identifiers. Whereas Affy-
metrix GeneChip provides a probeset identifier with a target
sequence, the obtained data sets from cDNA microarrays
provide only an accession number of the used clones. This
leads to the need for a large computational effort. Unfortu-
nately, most of the gene expression data have not been
published as raw data so far. Therefore, published articles
are the prevalent repository for differentially expressed
genes. Comparison of these data has its own merit [26],
but only analysis of the raw data circumvents the inherent
problems of microarrays within the field of data normalization
and expression level assignment. Moreover, comparison of
published data is hampered by different modes of gene
expression analysis, possibly leading to a subjective choice
of genes.
Within this set of analyzed genes, most of them have
never been assigned as differentially expressed. Also, only
a few genes are identified as differentially expressed in
more than five experiments (Figure 1, B and C). From
those data, we might conclude that a comparison of micro-
array data leads not to an accumulation of false positives
but to subsets of genes that might be worthwhile in further
analyses.
We were interested in those whose expression is
deregulated in a majority of tumors. Therefore, we decided
to concentrate on genes that are differentially expressed
in 8 of 11 analyzed tumors. We identified 100 genes as
commonly overexpressed and 21 as commonly downregu-
lated within carcinomas investigated. Interestingly, we were
able to identify more genes as commonly overexpressed
than genes commonly underexpressed in tumors. This
might be due to a higher variance of the observed gene
expression in normal tissues. This variance might result
from an inadequate low number of these tissues in indi-
vidual comparisons (i.e., there were only 4 normal breast
tissues and 68 tumor tissues analyzed by Sorlie et al. [19])
(Table 1). As normal tissue has to abide by the precise
function of an organ, which is different between organs, a
tumor has, first of all, the need to grow. To accomplish this
task, a tumor has to circumvent several safeguard func-
tions of cell maintenance and growth limitations [1]. To
bypass these, only a few genes have to be modified, which
might lead to a common tumor phenotype. Therefore, gene
expression of tumors of different organs might probably be
more homogenous than the gene expression of normal
tissues from the same organs.
Within the set of overexpressed genes, we identified
genes from different functional categories. Interestingly,
Figure 3. Grouping of identified genes into the molecular function categories of gene ontology using Fatigo (http://fatigo.bioinfo.cnio.es/). Red: Genes
overexpressed in tumors; green genes underexpressed in tumors.
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genes from the protein degradation pathway by the ubiquitin
ligation/proteasome pathway as well as transcription factors
were often found. Those genes have already been de-
scribed as overexpressed within tumors [1,27], therefore
demonstrating the feasibility of our approach. In addition,
these genes represent key members for new targets for
cancer therapy. Validation of differential expression is a key
for successful microarray experiments. This should also
refer to comparative or meta-analysis. However, tissue
samples of different tumor entities with an adequate number
of samples can rarely be obtained. We validated the differ-
ential expression of 8 of 100 overexpressed genes and
observed an overexpression in most cases. That not all
genes were overexpressed in all samples might be attrib-
uted to either the heterogeneity of gene expression in
tumors or perhaps errors of the sampling of tissues, or that
the gene was falsely assigned as differentially expressed by
our method.
Within the group of overexpressed genes, we identified
FOXM1 and ADAR1. FOXM1 is activated by the hedgehog
signalling pathway [28], indicating a common activation of
this elemental developmental pathway in cancers. ADAR is a
member of a diverse family of proteins involved in the editing
of mRNA. Overexpression of this gene might lead to a higher
amount of edited RNA and might therefore lead to mutated
proteins. A high level of ADAR within cancers therefore might
act as a mutator mutation. That enzymes of the RNA editing
pathway are capable of acting in this manner has been
shown for APOBEC [29].
In conclusion, using a novel approach to compare gene
expression data, we identified a set of genes that might be
useful in the further analysis of fundamental signal transduc-
tion pathways that lead to carcinomas.
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